These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12115253)

  • 1. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.
    Fautrel B; Foltz V; Frances C; Bourgeois P; Rozenberg S
    Arthritis Rheum; 2002 May; 46(5):1408-9; author reply 1409. PubMed ID: 12115253
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.
    van der Laken CJ; Lems WF; van Soesbergen RM; van der Sande JJ; Dijkmans BA
    Arthritis Rheum; 2003 Jan; 48(1):269-70. PubMed ID: 12528130
    [No Abstract]   [Full Text] [Related]  

  • 4. Intraarticular injection of anti-tumor necrosis factor: Comment on the letter by Arnold et al.
    Bliddal H
    Arthritis Rheum; 2004 Jun; 50(6):2037-8. PubMed ID: 15188385
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 6. Lessons from magnetic resonance imaging studies in rheumatoid arthritis.
    Quinn M
    J Rheumatol; 2008 Mar; 35(3):372-4. PubMed ID: 18322971
    [No Abstract]   [Full Text] [Related]  

  • 7. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipokine profile is modulated in subcutaneous adipose tissue by TNFα inhibitors in patients with rheumatoid arthritis.
    Šenolt L; Kuklová M; Cerezo LA; Hulejová H; Filková M; Bošanská L; Pecha O; Pavelka K; Haluzík M; Vencovský J
    Ann Rheum Dis; 2011 Nov; 70(11):2054-6. PubMed ID: 21622768
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 14. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 15. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept-associated SLE with lupus nephritis.
    Neradová A; Stam F; van den Berg JG; Bax WA
    Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471
    [No Abstract]   [Full Text] [Related]  

  • 17. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 19. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.
    Carlson E; Rothfield N
    Arthritis Rheum; 2003 Apr; 48(4):1165-6; author reply 1166. PubMed ID: 12687569
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue.
    Galassi G; Ariatti A; Codeluppi L; Meletti S
    Muscle Nerve; 2010 Aug; 42(2):296-8; author reply 298. PubMed ID: 20658603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.